Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain

Status unconfirmed · Phase 2

Conditions studied: Alopecia

In brief

Hair loss occurs commonly as a result of radiotherapy administered to the brain, and this can contribute to the distress and social isolation of patients with advanced cancer. In this study a topical gel will be applied directly to the scalp during each dose of radiotherapy. The goal is to determine to what extent the experimental drug is successful in lessening the hair loss.

Key facts

Study ID

NCT00801086

Run by

Mitos Pharmaceuticals

People needed

16

Starts

2008-11-01

Expected to finish

2010-06-01

Last updated by the study team

2008-12-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic cancer to the brain for which palliative whole brain radiotherapy is recommended.
• Hair that covers the scalp and is at least 1/4 inch in length

You may not qualify if…

• Receiving chemotherapy known to cause alopecia within 60 days of study or during the study.
• Pre-existing alopecia
• Previous brain radiotherapy
• scalp metastases or scalp wounds
• use of hair dyes

Where it is running

• University of Arizona — Tucson, Arizona, United States (enrolling)
• University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.